Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Heart failure therapeutic strategies

Yano, M., Okuda, S., Oda, T., Tokuhisa, T., Tateishi, H., Mochizuki, M., Noma, T., Doi, M., Kobayashi, S., Yamamoto, T., Ikeda, Y., Ohkusa, T., Ikemoto, N., and Matsuzaki, M. (2005) Correction of defective interdomain interaction within ryanodine receptor by antioxidant is a new therapeutic strategy against heart failure. Circulation 112, 3633-3643. [Pg.1130]

Chow MSS, Scheife RT, eds. Therapeutic and research strategies for congestive heart failure. Pharmacotherapy 1993 13 (5 pt 2) 71S-99. [Pg.810]

No single test is available to confirm the diagnosis of heartfailure. Because the syndrome of heart failure can be caused or worsened by multiple cardiac and noncardiac disorders, accurate diagnosis is essential for development of therapeutic strategies. Heart failure often is suspected initially in a patient based on the symptoms. These frequently will include dyspnea, exercise intolerance, fatigue, and/or fluid retention. However, it must be emphasized that signs and symptoms lack sensitivity for diagnosing heart failure because these symptoms are found frequently with other disorders such as pulmonary disease. Even in patients with known heart failure, there is poor correlation between the presence or severity of symptoms and hemodynamic abnormality. [Pg.228]

A possible novel therapeutic strategy for heart failure following myocardial infarction may be to increase the number of functional myocytes within the diseased area by the implantation of exogenous myogenic cells. Early studies used neonatal rat cardiomyocytes for transplantation, as these cells have cardiac phenotype and still retain some proliferation capacity [2-4]. Fetal cardiomyocyte cell grafts showed the formation of cell-to-cell contacts, complete with gap junction proteins [4]. Moreover, cultured human fetal cardiomyocytes were shown to survive, and fetal rat cardiomyocytes were shown to be present in the infarcted rats hearts for up to 6 months after transplantation [5]. Further studies in animal models of myocardial infarction showed that grafting of cardiomyocytes from fetal and neonatal sources was asso-... [Pg.294]

OTHER WATER-RETAINING STATES In patients with congestive heart failure, cirrhosis, or nephrotic syndrome, ejfective blood volume often is reduced, and hypovolemia frequently is exacerbated by the liberal use of diuretics. Since hypovolemia stimulates vasopressin release, patients may become hyponatremic owing to vasopressin-mediated retention of water. The development of potent orally active receptor antagonists and specific inhibitors of water chaimels in the collecting duct would provide an effective therapeutic strategy not only in patients with SIADH but also in the much more common setting of hyponatremia in patients with heart faftme, cirrhosis, or nephrotic syndrome. [Pg.508]

Cardiorenal actions of TRV120027, a novel 6-arrestin-biased ligand at the angiotensin II type I receptor, in healthy and heart failure canines A novel therapeutic strategy for acute heart failvu-e. Circulation. Heart Failure, 4, 770—US. [Pg.181]

McMullen, J.R. and G.L. Jennings. 2007. Differences between pathological and physiological cardiac hypertrophy Novel therapeutic strategies to treat heart failure. Clinical and Experimental Pharmacology and Physiology 34(4) 255-62. [Pg.276]


See other pages where Heart failure therapeutic strategies is mentioned: [Pg.103]    [Pg.103]    [Pg.860]    [Pg.206]    [Pg.439]    [Pg.310]    [Pg.43]    [Pg.713]    [Pg.860]    [Pg.806]    [Pg.293]    [Pg.310]    [Pg.321]    [Pg.324]    [Pg.328]    [Pg.329]    [Pg.329]    [Pg.331]    [Pg.294]    [Pg.315]    [Pg.576]    [Pg.120]    [Pg.271]    [Pg.264]    [Pg.92]    [Pg.286]    [Pg.806]    [Pg.114]   
See also in sourсe #XX -- [ Pg.120 ]




SEARCH



Therapeutic strategies

© 2024 chempedia.info